Menu

Neuroscientist Rahul Desikan Dies

He developed an MRI-based map of the human cortex, discovered genetic risk factors for neurodegenerative diseases, and wrote about his struggles with ALS.

Jul 19, 2019
Kerry Grens

Rahul Desikan, a neuroscientist at the University of California, San Francisco, died July 14 at age 41 from amyotrophic lateral sclerosis.

He was known for developing a widely used method of automatically labeling regions of the human cortex based on MRI data, called the Desikan atlas, and for identifying genetic variants related to a number of neurodegenerative diseases. In recent years, he had written about living with ALS, a disease he also happened to study.

“I went into medicine to take care of patients with brain diseases. Now, I have one of the diseases that I study,” Desikan said in a press release earlier this year. “Even with this lethal disease, I continue to find neurology fascinating and beautiful.”

Desikan was born in India in 1978 and grew up in New York City. He studied neuroscience at Boston University for his undergraduate and PhD and attended medical school there as well. During this time, he and his colleagues developed the Desikan atlas, which labels 34 regions of each hemisphere of the human cortex automatically using data from MRI scans.

“[It] quickly became one of the most widely-used tools in the neuroscience community, has been cited more than 4500 times,” Desikan’s UCSF colleague Christopher Hess writes in a memorial. “Color figures of the atlas in its various forms still fill the pages of our leading scientific journals.”

In 2015, he joined UCSF as a clinical fellow, two years later becoming a member of the faculty of Radiology & Biomedical Imaging, Neurology and Pediatrics, where he analyzed the genetics of neurodegenerative diseases.

According to a 2019 profile in Bostonia, it was in 2016, when Desikan’s team had just begun the largest study of ALS genetics to date, that he began to experience the symptoms of ALS. Several months later he was diagnosed with the fatal disease. “Even as Desikan is pouring his life into curing ALS, ALS is stealing the life he had,” the article states.

Desikan was nevertheless productive until the end of his life, publishing a number of papers on the genetic risk factors for ALS, Alzheimer’s, and other conditions. “People ask me, ‘What’s it like to work with him?’” postdoc Iris Broce told Bostonia. “I tell them, ‘He just texted me, I can’t keep up with him.’”

According to UCSF, Desikan leaves behind his wife, Maya Vijayaraghavan, who is a faculty member in the UCSF Department of Medicine, as well as two sons, his parents, and his sister.

Kerry Grens is a senior editor and the news director of The Scientist. Email her at kgrens@the-scientist.com.

December 2019

Markers of Alzheimer’s

Hints about brain health can be found in the blood

Marketplace

Sponsored Product Updates

Chemyx: Navigating Legal and Regulatory Requirements for Cannabis Research and Product Development in the United States
Chemyx: Navigating Legal and Regulatory Requirements for Cannabis Research and Product Development in the United States
Given its legal status as a controlled substance, researchers, producers, and developers still must be aware of a considerable number of regulatory guidelines and practices governing the cannabis industry.
Chemyx: Cannabis Extraction on the Cutting Edge
Chemyx: Cannabis Extraction on the Cutting Edge
Tully Stroud, Chief Scientific Officer for Elite Molecular Labs, talks about the growing field of cannabis extraction and refinement. 
Heart-on-a-Chip Technology Predicts Preclinical Systolic and Diastolic in vivo Observations for Novel Cardiac Drug in Development
Heart-on-a-Chip Technology Predicts Preclinical Systolic and Diastolic in vivo Observations for Novel Cardiac Drug in Development
TARA Biosystems, Inc. today reported in vivo and in vitro functional data from a study of investigational candidate, MYK-491, showing that TARA’s human iPSC-derived organ-on-a-chip technology can directly measure in vivo cardiac performance.